Cervical dissecting extravasation of oxaliplatin: A case report.
暂无分享,去创建一个
[1] X. Qian,et al. Proteomic analysis of cisplatin- and oxaliplatin-induced phosphorylation in proteins bound to Pt-DNA adducts. , 2020, Metallomics : integrated biometal science.
[2] S. Ho,et al. A Molecular Perspective , 2019 .
[3] F. Bahadori,et al. Management of extravasation of oxaliplatin by mimicking its biotransformation , 2018, Clinical and Translational Oncology.
[4] N. E. El Saghir,et al. Overview, prevention and management of chemotherapy extravasation. , 2016, World journal of clinical oncology.
[5] R. Mader,et al. Port-a-Cath extravasation of vesicant cytotoxics: surgical options for a rare complication of cancer chemotherapy. , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[6] S. E. Nielsen,et al. [Reversible tissue damage after paravasal infusion of oxaliplatin]. , 2015, Ugeskrift for laeger.
[7] F. Narducci,et al. Chemotherapy Drug Extravasation in Totally Implantable Venous Access Port Systems: How Effective is Early Surgical Lavage? , 2015, The journal of vascular access.
[8] T. Hickish,et al. A midline for oxaliplatin infusion: the myth of safety devices , 2014, BMJ Case Reports.
[9] A. Margulies,et al. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] R. Leon-Ferre,et al. Extravasation of oxaliplatin into the mediastinum: a case report and review of the literature. , 2012, Clinical advances in hematology & oncology : H&O.
[11] D. Conde-Estévez,et al. [Update in the management of extravasations of cytocytostatic agent]. , 2012, Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria.
[12] C. Fournier,et al. Totally implantable venous access port systems and risk factors for complications: a one-year prospective study in a cancer centre. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[13] M. Saif,et al. Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review , 2010, Metal-based drugs.
[14] Joan Ramon Soler,et al. Extravasation of oxaliplatin: an infrequent and irritant toxicity , 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[15] R. Wickham,et al. Vesicant extravasation part II: Evidence-based management and continuing controversies. , 2006, Oncology nursing forum.
[16] D. Goodsell. The molecular perspective: Cisplatin. , 2006, Stem cells.
[17] M. D. de Lemos,et al. Management of extravasation of oxaliplatin , 2005, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[18] H. Hochster,et al. Oxaliplatin: practical guidelines for administration. , 2004, Clinical journal of oncology nursing.
[19] P. Reichert,et al. Extravasations of oxaliplatin. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] M. Markman. Toxicities of the platinum antineoplastic agents , 2003, Expert opinion on drug safety.
[21] J. Zalcberg,et al. A case report of oxaliplatin extravasation. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] M. Baur,et al. Extravasation of Oxaliplatin (Eloxatin®) – Clinical Course , 2000, Oncology Research and Treatment.